Stakeholders and the media have engaged in robust conversations about the Mifepristone rulings’ impacts that extend beyond abortion to other FDA decisions regarding historical court deference to agency interpretation of statutes and regulations, approvals of products that may face political opposition, and access and coverage variations across states.